The following amendment has been
made to the "Update on US launch" announcement released on 2
September 2024 at 07:00 under RNS No. 3888C.
· The
subtitle has been updated to "Eroxon's availability online and in
stores"
All other details remain
unchanged.
2 September 2024
Futura
Medical plc
("Futura", "the Group" or the "Company")
Update on
US launch
Eroxon's
availability online and in stores
Futura Medical plc (AIM: FUM), the
consumer healthcare company behind Eroxon®, that specialises in the
development and global commercialisation of innovative and
clinically proven sexual health products, announces that as part of
Haleon's launch plan, as of 1 September 2024, Eroxon is available
for pre-order online for delivery in October and will also be
available in stores in the US from October 2024.
Contacts:
|
Futura Medical plc
|
James Barder
Chief Executive Officer
Angela Hildreth
Finance Director and COO
|
investor.relations@futuramedical.com
+44 (0)1483 685 670
www.futuramedical.com
|
|
Panmure Liberum
Nominated Adviser
and Broker
|
Emma Earl, Will Goode, Mark Rogers
(Corporate Finance)
Rupert Dearden (Corporate
Broking)
|
+44 (0)20 3100 2000
|
|
|
|
|
|
Stifel Nicolaus Europe Limited
Joint Broker
|
Alan Selby
Ben Maddison
Ben Good
|
+44 (0)207 710 7600
|
|
|
|
|
|
Alma
Strategic Communications
|
Rebecca Sanders-Hewett
Sam Modlin
Will Ellis Hancock
|
+44 (0)20 3405 0205
futura@almastrategic.com
|
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the
developer of innovative sexual health products, including lead
product Eroxon. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in
sexual health products.
Eroxon, Futura's clinically proven
lead product, has been developed for the treatment of Erectile
Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the
counter and helps men get an erection in ten
minutes, addresses significant unmet needs in the ED
market.
ED impacts 1 in 5 men globally across
all adult age brackets, with approximately half of all men over 40
experiencing ED and 25% of all new diagnoses being in men under
40.
Futura has distribution partners in
place in a number of major consumer markets including Haleon in the
US, the largest market for ED in the world, and Cooper Consumer
Health in Europe. Eroxon has been nominated for a number of
healthcare industry awards and has won two to-date.